Molecular Biosystems FS069 contrast agent: 90% of patients show improved echocardiography imaging.
This article was originally published in The Gray Sheet
Executive Summary
MOLECULAR BIOSYSTEMS' FS069 ENHANCES ECHOCARDIOGRAPHY IMAGES IN 90% OF PATIENTS in a Phase III trial of the ultrasound imaging agent, the company reports in a July 17 press release. Use of FS069 (perfluoropentane encapsulated microspheres) improved endocardial border delineating (EBD) and left ventricular opacification (LVO) in 90% of patients, the firm says. In addition, FS069 showed statistically significant (p<.0001) improvement in EBD, LVO and Doppler signal enhancement compared to MBI's first approved contrast agent, Albunex (albumin-based ultrasound microspheres).
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.